Tübingen's messenger RNA vaccine and drug developer's latest round includes a $171m investment by strategic partner GlaxoSmithKline.

CureVac, a Germany-based RNA therapy spinout of Eberhard Karls University of Tübingen, closed a $640m financing round on Tuesday that included $171m from pharmaceutical firm GlaxoSmithKline, which signed a strategic partnership with it this week.
The round includes $343m in the form of the funding commitment made by German development bank KfW last month and $126m in additional funding from investors including sovereign wealth fund Qatar Investment Authority.
CureVac is developing therapeutics designed to leverage mRNA…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?